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The Usefulness of Brain Natriuretic Peptide
in Complex Congenital Heart Disease
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Jannet A. Eindhoven, MD, Annemien E. van den Bosch, MD, PHD, Philip R. Jansen, MSC,
Eric Boersma, PHD, Jolien W. Roos-Hesselink, MD, PHD
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Brain natriuretic peptide (BNP) and N-terminal pro–brain natriuretic peptide (NT-proBNP) are well-established markers
for heart failure in the general population. However, the value of BNP as a diagnostic and prognostic marker for pa-
tients with structural congenital heart disease (CHD) is still unclear. Therefore, the purpose of this study was to evalu-
ate the clinical utility of BNP in patients with CHD. We executed a PubMed literature search and included 49 articles
that focused on complex congenital heart defects such as tetralogy of Fallot, systemic right ventricle, and univentricu-
lar hearts. Data on BNP measurements and cardiac function parameters were extracted. In all patients after correc-
tion for tetralogy of Fallot, BNP levels were elevated and correlated significantly with right ventricular end-diastolic
dimensions and severity of pulmonary valve regurgitation. Patients with a systemic right ventricle had elevated BNP
levels, and positive correlations between BNP and right ventricular function were seen. In patients with a univentricu-
lar heart, elevated BNP levels were observed before completion of the Fontan circulation or when patients were symp-
tomatic; a clear association between BNP and New York Heart Association functional class was demonstrated. In con-
clusion, this review shows an overall increase in BNP values in complex CHD, although differences between types of
congenital heart anomaly are present. As BNP values differ widely, conclusions for individual patients should be
drawn with caution. Further investigation with sequential BNP measurement in a large, prospective study is warranted
to elucidate the prognostic value of BNP assessment in patients with CHD. (J Am Coll Cardiol 2012;60:2140–49)
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fCongenital heart disease (CHD) is the most prevalent form of
congenital abnormality with an incidence of approximately 9
cases per 1,000 live births (1). The number of adult patients
with a congenital heart disease is steadily increasing due to the
success of pediatric cardiology and open-heart surgery. How-
ever, few cardiac surgical repairs are curative. At adult age,
many patients will have complications as valvular dysfunction
and arrhythmias. The increasing number of adult CHD
patients also brings an increasing number of patients at risk of
late ventricular dysfunction and heart failure. That is mainly
seen in the more complex congenital heart diseases, such as
tetralogy of Fallot (TOF), defects with a systemic right
ventricle (RV), and univentricular hearts.
Brain natriuretic peptide (BNP) and N-terminal pro–B-
type natriuretic peptide (NT-proBNP) have gained a lot of
interest in the last 20 years (2). These hormones are
synthesized and released into the circulation by the ventric-
ular myocytes in response to pressure overload, volume
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2012, accepted February 7, 2012.expansion, and increase in myocardial wall stress. Within
the myocytes, the precursor pro-BNP is divided in the
biologically active form BNP and the inactive NT-proBNP
fragment. Once in the circulation, BNP has natriuretic,
diuretic, and vasodilatory effects on the internal climate (2).
oth markers show a comparable clinical utility for assessing
ardiac impairment and are well-established markers of
eart failure in the general population (3).
Natriuretic peptides might be of clinical importance in
he congenital heart disease population because of their
roven usefulness in acquired heart disease and the simplic-
ty of assessment. Their role in the diagnostic approach and
linical decision making in patients with CHD is not well
efined. In this systematic review, we evaluate the recent
iterature on BNP and NT-proBNP activation and the
elationship between these biomarkers and cardiac function
n patients with complex congenital heart disease.
ethods
earch strategy, selection criteria, and data extraction.
n September 1, 2011, a PubMed literature search with
ocus on complex cardiac defects (including TOF, systemic
V, and univentricular hearts) was conducted. Data from
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Medical Subject Headings and text key words were used: “natri-
uretic peptide, brain” or “pro-brain natriuretic peptide” and “heart
defects, congenital” or “tetralogy of Fallot” or “transposition of
great vessels” or “Fontan procedure” or “Norwood procedure” or
“congenitally corrected transposition of the great arteries.”
Each article title and abstract was screened to identify
relevant studies. The search strategy was limited to articles
concerning human subjects that were published in the
English language. Articles concerning both children and
adult patients were included. The BNP levels had to be
reported per cardiac diagnosis. Consequently, articles that
presented BNP levels for a group of CHD diagnoses were
excluded. We focused on complex cardiac defects because of
the relative high incidence of adverse events as heart failure
in these groups. Atrial septal defects and ventricular septal
defects, aortic coarctation, congenital aortic stenosis, and
persistent ductus arteriosus, although also of interest, were
excluded in the current study. References of selected papers
were crosschecked with the same inclusion and exclusion
criteria to identify articles missed by the search strategy.
Data were extracted on type of CHD, age, sex, plasma
BNP levels, and BNP immunoassay method. Furthermore,
when reported in the article, BNP levels of controls, type of
controls, and correlations between BNP and cardiac func-
tion parameters measured with echo, cardiac magnetic
resonance (CMR) imaging, exercise test, New York Heart
Association (NYHA) classification, reinterventions, and
adverse events were collected. In all potentially relevant
articles, eligibility was assessed by 2 authors (J.A.E. and
J.W.R.H.). Disagreements were resolved by discussion.
Because of the heterogeneity in functional tests and result
presentation, a formal meta-analysis linking BNP levels
with functional parameters and outcome could not be
conducted. In this article, both markers, BNP and NT-
proBNP, will further be referred to as “BNP” unless a
separate use is needed for clarification.
Results
The literature search yielded 200 potential eligible studies
(Fig. 1). We excluded 51 articles because BNP levels for 1
CHD were reported without specification of BNP levels per
diagnosis or age at time of assessment. In addition, 38
reports focusing on relative mild cardiac defects including
atrial septal defect, ventricular septal defect, aortic coarcta-
tion, and persistent ductus arteriosus were excluded. Finally,
49 studies concerning TOF (n  20), systemic RV (n 
13), or single ventricle morphology (n  16) were included
in this systematic literature review. The main diagnostic
tools used to quantify cardiac function were physical exam-
ination, echocardiography, and CMR imaging. Further,
occasionally results of cardiopulmonary exercise tests, car-
diac catheterization, or cardiac computed tomography scan
were reported. Longitudinal data were available in 6 of the
49 studies.Tetralogy of Fallot. The value
of BNP in patients with surgi-
cally repaired TOF has been
studied in 20 articles describing a
total of 770 patients with a me-
dian/mean age ranging from 4.2
to 30.9 years (4–23). The BNP
levels were significantly higher in
Fallot patients (mean/median
values of BNP and NT-proBNP
ranging from 19 to 85 pg/ml and
from 85 to 231 pg/ml, respec-
tively) when compared to age-
and sex-matched controls (mean/
median values of BNP and NT-
proBNP ranging from 6 to 15.4
pg/ml and from 38 to 111 pg/ml,
respectively), although most pa-
tients were asymptomatic or
only mildly symptomatic (Fig. 2)
(5–10,12,14,16,17). Patients with
NYHA functional class II revealed
significantly higher BNP values than
patients with NYHA class I (p  0.01) (Table 1) (12,15).
The severity of pulmonary valve regurgitation and RV
end-diastolic volume showed a positive correlation with
BNP in 7 of 9 studies (Table 1) (6,9,11,12,15–19). A great
variety between correlations of BNP with RV function was
seen, ranging from nonsignificant correlations up to highly
significant correlations of 0.60 in comparable study popu-
lations using the same diagnostic tools. In none of the
studies was a correlation observed between BNP and left
ventricle (LV) function or LV end-diastolic volume.
In 7 studies, an exercise test was performed (6,7,9,15–18).
Plasma BNP correlated negatively with exercise capacity
and peak oxygen uptake (8,15–17). Furthermore, TOF
patients had more pronounced increases in BNP levels
post-exercise compared with healthy controls (17).
Three studies with longitudinal data revealed a significant
decrease of BNP levels 6 months or longer after pulmonary
valve replacement compared with BNP levels before the
intervention, mirroring the smaller RV end-diastolic volume
and/or improved RV ejection fraction (4,15,23).
Systemic RV. In 13 studies (24–36), levels of BNP were
reported for patients with a systemic RV, including patients
with transposition of the great arteries (TGA) after atrial
switch operation (Mustard or Senning) and congenitally
corrected TGA. A total number of 469 patients with a
systemic RV were studied for BNP levels. All patients were
included at adult age (mean/median age ranging from 19 to
35 years). The BNP levels were higher in systemic RV
patients (mean/median BNP and NT-proBNP values rang-
ing from 13.5 to 98 pg/ml and from 200 to 654 pg/ml,
respectively), compared with controls (median BNP 17
pg/ml, range of mean NT-proBNP 48 to 57 pg/ml) in most
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CHD  congenital heart
disease
CMR  cardiac magnetic
resonance
LV  left ventricle
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
RV  right ventricle
TCPC  total
cavopulmonary connection
TGA  transposition of the
great arteries
TOF  tetralogy of Fallot
TR  tricuspid valve
regurgitationstudies, even when no signs or symptoms of heart failure
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BNP levels and NYHA functional class was reported in 3
studies (Table 2) (27,29,33).
A significant negative correlation between BNP levels
and RV function measured by either CMR or echocardi-
ography was found in 5 of 8 studies (correlation coefficients
ranging from r  0.42 to r  0.54) (Table 2)
24,25,29,33,34). Secondly, a weaker but still significant
ositive correlation between BNP and end-diastolic RV
olume was observed (24,25,29,33). Furthermore, a positive
orrelation was found between the severity of tricuspid valve
egurgitation (TR) and BNP (27,35). In contrast, LV
unction did not correlate with BNP in any of the studies.
In 5 studies, exercise tests were performed (25,27,28,32,34).
lasma BNP correlated negatively with peak oxygen con-
umption in 3 of these studies. When comparing atrial
witch patients with congenitally corrected TGA, no sig-
ificant differences in BNP levels were found (26,27,31).
urthermore, 1 study reported longitudinal data of 14
atients (median follow-up 1.4 years) and observed no
ifferences in BNP levels (no changes in clinical findings
Figure 1 Literature Search and Selection
Numbers of articles for each step of the process are indicated. After reading titles
in the Methods section. Another 48 articles were excluded after evaluation of full
heart disease; PDA  persistent ductus arteriosus; VSD  ventricular septal defeere identified either) (27).ingle ventricle. Sixteen studies reported data on BNP in
atients with univentricular hearts and Fontan physiology
37–52), including a total of 1,185 patients. The studied
ontan patients mainly comprised children (mean/median
ge ranging from 0.6 to 33.1 years). Patients treated with a
lassic Fontan procedure had significantly higher levels of
NP compared with patients who had undergone the
urrently used Fontan approach (Fig. 2, Table 3) (40,42,48).
Young patients after the first palliative operation revealed
higher BNP levels than patients after the bidirectional
Glenn procedure or completion of the Fontan circulation
with a total cavopulmonary connection (TCPC) (39,41).
After completion of the Fontan procedure by TCPC, the
BNP values of asymptomatic patients were comparable to
those of healthy age-matched controls (39–41,44,47,48).
However, symptomatic patients defined as NYHA class 2
or New York University Pediatric Heart Failure Index 5
ad significantly higher levels of BNP than did asymp-
omatic patients (Table 3) (38,40,49,50). The New York
University Pediatric Heart Failure Index score is an
alternative instrument for measuring heart failure severity
bstract, 103 articles were excluded on the basis of the exclusion criteria named
SD  atrial septal defect; BNP  brain natriuretic peptide; CHD  coronaryand a
text. A
ct.in children (53).
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ular valve regurgitation showed a positive correlation with
BNP values (38). There was 1 study reporting a correlation
between variables of diastolic function and BNP (44). No
correlations were found between ventricular systolic func-
tion and BNP (44,45). When focusing on ventricular
morphology, 2 studies found higher BNP levels in patients
with an anatomical RV compared with patients with LV
morphology (39,49), whereas 4 other studies, including a
large study of 510 Fontan patients, did not find this
anatomy-based difference (38,40,48,50).
In 7 of the 16 studies, an exercise test was performed.
Only 1 study demonstrated a significant correlation between
BNP and peak oxygen consumption in Fontan patients (40),
whereas 3 other studies found no significant correlation
(39,49,51). Mixed results were also found for pulse oxymet-
ric saturation and plasma BNP.
Follow-up data revealed significantly higher levels of
BNP in 5 patients who died from heart failure during the
study period (38). Another study, however, found no
prognostic value of BNP during 4 years of follow-up,
including events in 11 patients (46).
Discussion
This systematic review demonstrates that BNP is a potential
robust clinical marker for functional status and cardiac
function in congenital heart disease. Although most studies
were performed cross-sectional and originally not designed
to assess BNP, some conclusions can be drawn. Plasma
Figure 2 BNP and NT-proBNP Measurements per Cardiac Diagn
Mean/median values of brain natriuretic peptide (BNP), N-terminal pro–B-type natr
Each symbol reflects 1 study patient population or control population. Red circles
controls, mean; blue triangles indicate controls, median. One result was left out o
cle patients).BNP was increased in complex CHD compared withcontrols or reference values, even when patients were
asymptomatic. Exceptions to this finding are asymptomatic
patients after TCPC; their BNP levels were comparable to
those of healthy control patients. This review shows that,
despite the overall increase in BNP, a wide range of BNP
values is measured in most studies, and therefore, conclu-
sions for individual patients should be drawn with caution.
The studies with TOF and systemic RV patients mainly
included asymptomatic and mildly symptomatic patients
(NYHA I and II), and therefore, BNP values of more
symptomatic patients (NYHA III to IV) are still uncertain.
In contrast, in Fontan patients, strong positive correlations
were found between BNP and NYHA class when all
functional classes were studied.
Natriuretic peptides are known to be age and sex depen-
dent (54), and accordingly, reference values for BNP and
NT-proBNP were mainly obtained from age- and sex-
matched controls. In line with this assumption, the majority
of the studies found higher BNP values in older patients,
and female patients revealed higher levels of BNP than men
(48). However, age-adjusted reference values of BNP were
not always used, which could explain discrepancies between
study conclusions. Also, inappropriate controls subjects
were used, including patients with (repaired) left-to-right
shunts (8,24,44) or Kawasaki disease (40).
Another potential direct cause of increased BNP produc-
tion, hypoxia, could influence the results in single ventricle
patients, as cyanosis is a common finding in uncorrected or
peptide (NT-proBNP), and age for patients and controls per cardiac diagnosis.
te patients, mean; red triangles indicate patients, median; blue circles indicate
gure to retain clarity (mean BNP 399 pg/ml by Law et al. [41] for single ventri-osis
iuretic
indica
f the fipartially corrected patients (55). However, correlations be-
Tetralogy of FallotTable 1 Tetralogy of Fallot
First Author
(Ref. #)
Baseline Characteristics Natriuretic Peptides BNP/NT-proBNP and Cardiac Function Parameters
n
Age
(Yrs)
NYHA
Class
Function
Assessment
Age at
Repair
(yrs)
BNP
(pg/ml)
NT-proBNP
(pg/ml)
RV
Function
(r)
RVEDV
(r)
TR
Vmax
(r)
PR
Severity
(r)
NYHA
Class
Peak
VO2
(r)
Apitz (13) 16 14.2 (9.8–24.9) I MRI 1.2 (0.2–4.5) 19 (7–42) NS
Brili (10) 25 28.4 8.3 I, II Echo 18.8 6.7 85 87 NS
Cheung (16) 32 14.7 3.1 I, II, III Echo 4.6 2.5 21.9 (7.8–470) NS 0.72 NS 0.43
p  0.001 p  0.03
Cheung (16) 32 14.7 3.1 I, II, III MRI 4.6 2.5 21.9 (7.8–470) NS 0.6 0.46 0.43
p  0.009 p  0.01 p  0.03
Cetin (12) 25 14.1 4.4 I, II Echo 4.9 5.1 28.3 24.1 0.60 0.7 0.6 
p  0.0001 p  0.0001 p  0.0001 p  0.0001
Dodge-Khatami (23) 23 13.2 (5.3–19.6) I, II MRI 1.6 (0.3-4.6) 231 228 0.47 NS
p  0.05
Festa (9) 70 21 1 I, II MRI/Echo 3.4 0.3 218 30 0.32 0.40 0.27 NS 0.57
p  0.01 p  0.001 p  0.05 p  0.001
Ishii (17) 26 9.6 3.3 Echo 2 to 3 44 34 0.42 NS 
p  0.03 p  0.05
Khositseth (19) 21 12.1 2.5 I Echo/MRI 4.48 1.68 195 303 NS 0.57
p  0.01
Koch (15) 130 16.1 7.1 I, II Echo 13 6.5 24 (5–196) NS 0.20 I vs. II NS
p  0.029 p  0.012
Norozi (6) 50 27.8 1.7 I, II Echo 7.3 0.7 166 25 0.45 0.42  0.63
p  0.05 p  0.01 p  0.01 p  0.001
Tatani (11) 49 14.7 10 I, II Echo 5.4 5.3 211 219 NS 0.41 0.60
p  0.003 p  0.001
Trojnarska (7) 60 27.6 8.2 I, II Echo 7.5 5.3 34.8 27.1 NS 0.29
p  0.03
Van den Berg (18) 51 15 (7–26) MRI 0.8 (0.2–2) 85 (17–355) NS NS 0.005 NS
p  0.05
Wand (14) 21 11.6 5.2 I, II Echo Mean 1.7 Median 202 0.5 NS
(0.1–5) p  0.02
Values are mean  SD or median (range). BNP levels were determined by Triage BNP immunoassay (Biosite Diagnostics, La Jolla, California,), IRMA (Shionoria, Shionogi, Japan) and ADVIA Centaur BNP (Siemens Healthcare Diagnostics, Deerfield, Illinois). NT-proBNP was
evaluated with ECLIA (Elecsys, Roche Diagnostics, Basel, Switzerland).
Echo echocardiography; MRImagnetic resonance imaging; NS not significant; NYHA New York Heart Association; positive correlation, not further specified; PR pulmonary regurgitation; (r) correlation coefficient; RV right ventricular; RVEDV right
ventricular end-diastolic volume; TR Vmax  tricuspid regurgitation maximum velocity; VO2  volume oxygen uptake.
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Systemic Right VentricleTable 2 Systemic Right Ventricle
First Author
(Ref. #)
Baseline Characteristics Natriuretic Peptides BNP/NT-proBNP and Cardiac Function Parameters
n
Diagnosis/
Surgery
Age
(yrs)
NYHA
Class
Function
Assessment
BNP
(pg/ml)
NT-proBNP
(pg/ml)
RV
Function
(r)
RVEDV
(r)
RVESV
(r)
TR
Severity
(r)
NYHA
Class
Peak
VO2
(r)
Chow (24) 44 Senning 19.7 4 Echo 19 (6–522) 0.43 0.37
Mustard p  0.001 p  0.009
Dore (34) 29 Mustard 30.9 10.9 I, II Echo 258 243 0.42 NS
ccTGA p  0.02
Garg (28) 24 Mustard 24 (15–37) MRI or 15.4 18.2 NS NS NS NS
ccTGA ERNA
Koch (27) 48 Mustard 19 5 I, II Echo 20 (5–198) NS NS 0.5 I vs. II 0.35
ccTGA p  0.001 p  0.028 p  0.02
Kozelj (33) 19 ccTGA 35 13.1 all Echo 654 1535 0.53 0.50 0.61 NS 0.49
MRI or CT p  0.02 p  0.026 p  0.006 p  0.032
Norozi (32) 33 Mustard 23.4 7.4 I, II, III Echo 240 230 NS 0.46
p  0.03
Plymen (29) 35 Mustard 29 (18–40) I, II MRI 322 288 0.54 0.43 0.53 I vs. II
Senning p  0.001 p  0.01 p  0.001 p  0.02
Schaefer (25) 43 Mustard 29 4 Echo/MRI 200 148 0.46 0.32 0.32
p  0.002 p  0.044 p  0.04
Vogt (35) 16 Mustard 25.6 3.7 I, II, III Echo 67.3 47.5 NS 0.55 NS
Senning p  0.03
Values are mean  SD or median (range). The BNP levels were determined by Triage BNP immunoassay (Biosite Diagnostics), IRMA (Shionoria), or ADVIA Centaur (Siemens). The NT-proBNP was evaluated with ECLIA (Roche Diagnostics).
ccTGA  congenitally corrected transposition of the great arteries; ERNA  equilibrium radionuclide angiography; RVESV  right ventricular end-systolic volume; other abbreviations as in Table 1.
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First Author
(Ref. #)
Baseline Characteristics Natriuretic Peptides BNP/NT-proBNP and Cardiac Function Parameters
n Surgery
Age
(yrs)
NYHA
Class
Function
Assessment
BNP
(pg/ml)
NT-proBNP
(pg/ml)
VEDV
(r)
LV vs. RV
Morph.
AVR
(r)
NYHA
Class
Peak
VO2
(r) SaO2
RA
Pressure
(r)
Diastolic
Function
(r)
Atz (48) 510 Fontan§ Mean 11.9 Echo 13 (4–652)  NS NS NS
(6–18) MRI p  0.01
Holmgren (39) 38 Shunt 0.5 (0.–-0.9) Echo 32 (8–1220) p  0.02‡ NS
Glenn 3 (1.6–3.7) 6.7 (0–16)
TCPC 12 (5.2–17.9) 9 (0–39)
Inai (46) 50 Fontan§ 22.7 3.6 I, II Cardiac 91 14 NS
cath.
Koch (38) 67 TCPC 13.8 5.8 I, II Echo 13 (5-290) NS 0.38 I vs. II NS
p  0.002 p  0.035
Law (41) 33 APC 5.2 (0.3–37.8) All Echo or Median 84 0.54
BDG cardiac Median 38 p  0.04
Fontan§ cath. Median 38
Lechner (50) 59 TCPC 8.4 (2.1–25) All† Echo 96 (11–376) NS r2  0.44†
p  0.001
Lechner (49) 78 BDG
(CHF)
3.2 (0.9–9.8) All† Echo and 670 (290–39,763) p  0.05 0.90† NS 0.375
cardiac p  0.001 p  0.013
BDG
(CHF)
cath. 171 (32–335)
Man (44) 35 Fontan§ 13.7 5.3 Echo 21 (5–397) NS 0.31
p  0.009
Motoki (51) 68 Fontan§
(young)
21.2 1.1 All Echo 33 27  NS
p  0.05
Fontan§
(adult)
31.7 7.8 83 96
Cyanotic
SVP
33.1 9.29 227 235
Ohuchi (40) 97 Fontan§ 14 5 All Cardiac 46 76   0.24 NS II vs. III, IV 0.21   0.34
cath. p  0.0001 p  0.01 p  0.05 p  0.0001
Robbers-Visser (45) 28 TCPC 10 (6.8–20.7) MRI 98 (25–483) NS NS
Values are mean  SD or median (range). †Functional class measured by New York University Pediatric Heart Failure Index (NYUPHFI) score (53). ‡After second palliative step. §Fontan, both TCPC and right atriopulmonary connection or right atrioventricular connection.
The BNP levels were determined by Triage BNP immunoassay (Biosite Diagnostics), IRMA (Shionoria), or ADVIA Centaur (Siemens). The NT-proBNP was evaluated with ECLIA (Roche Diagnostics).
APC aortopulmonary connection; AVR atrioventricular valve regurgitation; BDG bidirectional Glenn;  beta coefficient; cath. catheterization; CHF with congestive heart failure; CHF without congestive heart failure; LV left ventricle; RA right atrium;
SaO2  oxygen saturation; SVP  single ventricle patients; TCPC  total cavopulmonary connection; VEDV  ventricular end-diastolic volume; other abbreviations as in Table 1.
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strable in these patients.
Tetralogy of Fallot. Since Lillehei et al. (56) reported the
first intracardiac surgical TOF repair in 1954, the outcome
of patients after corrective surgery has improved over the
years. Despite an increasing post-operative survival, pulmo-
nary valve regurgitation and RV dilation and dysfunction
often occur. Plasma BNP correlated with RV dilation and
severity of pulmonary regurgitation in the majority of the
studies. Together with the observed correlation between
BNP and exercise capacity, these findings may have impor-
tant clinical implications. The BNP measurement could
contribute to the timing of pulmonary valve replacement in
TOF patients with PR. However, the studies that have been
conducted so far cannot be used to resolve this important
issue, because most studies present cross-sectional data.
Although 3 longitudinal studies found elevated BNP levels
before pulmonary valve replacement, which decreased after-
wards, results of individual BNP measurements differ
widely. Large prospective studies are warranted to elucidate
the true prognostic value of BNP in these patients.
Interestingly, Van den Berg et al. (18) failed to observe a
correlation between NT-proBNP and RV size, presumably
because their results on NT-proBNP, functional reserve, and
exercise performance were overall within normal ranges, re-
flecting the good clinical condition of their study population.
Despite these findings the (modest) changes found in NT-
proBNP were related to relevant RV loading condition abnor-
malities, worse functional capacity, and decreased functional
reserve, confirming the diagnostic potential of BNP (18).
Systemic RV. A ventricle with right ventricular morphol-
ogy is not designed to pump as a systemic ventricle, which
may lead to late RV dysfunction. The treatment of systemic
ventricular dysfunction is challenging, and early detection is
crucial. The BNP was positively correlated with RV dys-
function in most studies. One of the 3 studies that failed to
demonstrate a correlation between BNP and RV function
did find a strong negative correlation between RV ejection
fraction and atrial natriuretic peptide (28), which is remark-
able because of the very close correlation between atrial
natriuretic peptide and BNP that is reported in adult CHD
patients (57). Maybe the atria play a pivotal role, whereas
Mustard and Senning patients have extensive atrial scars due
to surgery. In addition, TR often coexists and tends to
worsen progressively. Although Ebstein’s anomaly may be
present, in most cases, TR is secondary to annular dilation
from RV failure, and tricuspid valve replacement is not
convincingly helpful. Therefore, early detection of an in-
crease in TR is needed. The BNP could contribute to this
detection as a strong correlation was observed between
plasma BNP and TR severity in several studies. One
study by Kozelj et al. (33) could not confirm these
findings, maybe due to their relatively small study pop-
ulation, which might have been underpowered to dem-
onstrate a correlation. In addition BNP was correlated
with RV end-diastolic volume in most studies. OnlyKoch et al. could not demonstrate a relation between
BNP and end-diastolic RV diameter (27). Although, as
they say, their retrospective study design has led to
echocardiographic assessment of RV dimensions by vari-
able investigators over several years, which might not
have been accurate enough to detect a correlation.
Single ventricle. Patients with univentricular hearts and a
Fontan circulation comprise a large scala of CHD. Ventric-
ular function is crucial in the long-term prognosis of Fontan
patients. Because of the variable and enlarged ventricular
anatomy reliable estimates of ventricular function with
echocardiography are difficult to obtain and, preferably,
CMR imaging should be used. Nevertheless, Robbers-
Visser et al. (45) could not demonstrate a correlation
between CMR-derived function parameters, primarily be-
cause the majority of patients presented with BNP levels
within the normal range.
Interestingly, BNP levels in asymptomatic patients after
TCPC were comparable to those of healthy controls, unlike
BNP levels in asymptomatic Fallot or systemic RV patients.
Completion of the Fontan circulation will cause unloading of
the ventricle, which could explain lower BNP as BNP relates
with ventricular volume load. However, a strong correlation
between BNP and severity of heart failure was found in
symptomatic patients. Therefore, BNP assessment in patients
after TCPC may indeed contribute to early detection of heart
failure.
Study limitations. Most studies were performed cross-
sectionally and originally not designed to assess BNP.
Furthermore, overall investigated patient numbers were
small, the used cardiac function parameters varied largely,
and limited follow-up data are currently available. There-
fore, future research should be done in a large prospective
study, preferably with sequential BNP and cardiac function
assessment to determine the true prognostic value of BNP
for patients with CHD.
Conclusions
This systematic review has demonstrated BNP levels to be
elevated in patients after correction for tetralogy of Fallot
and in patients with a systemic RV, whereas BNP mainly
correlated with end-diastolic RV dimensions and pulmo-
nary regurgitation in Fallot patients and RV function in
systemic RV patients. Patients with a univentricular heart
had elevated BNP levels before completion of the Fontan
circulation or when symptomatic, revealing a clear associa-
tion between BNP and NYHA class. However, to elucidate
the prognostic value of BNP assessment in CHD, a large,
well-designed, prospective study is warranted.
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